Optiscan Imaging Limited · ASX:OIL
Optiscan Imaging — Shareholder Meeting (November 2001)
30 slides from Optiscan Imaging's shareholder meeting presentation, Nov 8, 2001
Slide 1: Optiscan Imaging Limited Annual General Meeting
Optiscan Imaging Limited Annual General Meeting 8th Nov 2001 Managing Director’s Address Unlocking the world of Live Micro Imaging (LMI) technology
Slide 2: Today's Presentation Will Cover
TODAYS PRESENTATION WILL COVER • A brief review of our products and how they will be developed and brought to market • Market information and current marketing activities • A brief update on our continuing development activities • A review and update on corporate issues
Slide 3: Live Micro Imaging (LMI)
Live Micro Imaging (LMI) • In vivo microscopy • Miniaturised devices • Immediate imaging of live cells • Microscopic, sub-cellular view (~1000x) • Non-invasive: no surgical removal of tissue • Live computer screen image • Internet ready • Anticipated long term cost savings
Slide 4: Patented Fibre Optic Confocal System
Patented Fibre Optic Confocal System Detector Scan mechanism Beamsplitter Laser (**Patented) Optical fibre Objective (**Patented) Specimen Focal plane
Slide 5: Patented Miniaturised Scanner
Patented Miniaturised Scanner • Key to Flexible Endoscopes
Slide 6: Medical Applications
Medical Applications Ear, nose & throat Respiratory Skin Stomach Microsurger Colon Keyhole Cervix
Slide 7: Instrument Development Pipeline
Instrument Development Pipeline Endoscopes for... Orthopaedics Head & Neck O&G (cervix) Urology Clinical Trial Grade Prototypes Flexible endoscope Clinical Trial Grade Prototype Stratum FDA - class I medical examination device
Slide 8: Introduction of new medical devices
Introduction of new medical devices • Step 1 - Preliminary clinical work & Pre-marketing • Step 2 - Regulatory approvals (FDA) • Step 3 - Establishment with market leaders • Step 4 - Initial sales (early adopters) • Step 5 - Maturation of applications • Step 6 - Mainstream sales and marketing to bro
Slide 9: Optiscan Stratum
Optiscan Stratum • Skin Cancer • Psoriasis • Inflammatory Lesions • Pharmaceuticals • Cosmetics • Dermatology research • FDA exempt - class I medical examination device • List Price - approx. US $75,000
Slide 10: LMI of Intact Human Skin
LMI of Intact Human Skin PapillaryBasale Stratum Granulosum Spinosum Dermis Corneum Dysplastic Junctional Naevus (a pre-cancerous mole)
Slide 11: Clinical Dermatology Atlas
Clinical Dermatology Atlas • Benign Naevi (moles) – both compound & junctional • Dysplastic Naevi (moles) – both compound & junctional • Basal Cell Carcinomas (BCCs) • Squamous Cell Carcinomas (SCCs) • Melanoma – levels 1 & 2 • Hutchinson’s Melanotic Freckle • Lentigo • Seborrheic Keratosis • Intra-
Slide 12: Clinical & Research Partners
Clinical & Research Partners • USA • Memorial Sloan-Kettering Cancer Center (NY) • Medical College of Wisconsin (WI) • University of California, Davis (CA) • University of Pittsburgh (PA) • Australia • Gold Coast Skin Centre (QLD)
Slide 13: Stratum Market Info
STRATUM MARKET INFO • Initial market comprises “early adopters” & clinical researchers • Leading dermatology research institues • Pharmaceutical companies • Cosmetics companies • Sales expected to be modest for 1 to 2 years.
Slide 14: Stratum Market Info
STRATUM MARKET INFO USA * Australia New skin cancers cases pa 1.3 million pa 270,000 (melanoma) ** (51,400) (8,366) Skin cancer deaths pa 9,800 1,100 pa (melanoma) ** (7,800) (900) Direct cost of skin cancers US $2.7 billion ~AUD $300 million Indirect costs of skin cancers US $2.6 billion ~AUD $300
Slide 15: Production Status
Production Status • Initially 13 Stratums built • Presently building further 8 • Future runs - 8 to 25 (based on need for next 1 to 2 years) • Capacity is ~200 per year (present design & staff) • Increased capacity is manageable as as demand rises
Slide 16: World Medical Devices Markets
World Medical Devices Markets Germany 30% of European market Japan ~12% of Europe world ~ 30% of market world market USA ~ 45% of Australia/NZ world < 5% of world market market
Slide 17: Stratum Sales & Distribution
Stratum Sales & Distribution • Australia/NZ • Direct from Optiscan HQ • USA • Optiscan Inc. • Germany, Austria, Switzerland • Distributor appointed - Lawrenz
Slide 18: Flexible Endomicroscope
Flexible Endomicroscope • Colon Cancer • Crohns Disease • Ulcerative Colitis • Barrett’s Oesophagus • Gastric Cancer Flexible Endomicroscope
Slide 19: Rigid Endoscopes
Rigid Endoscopes • Head and Neck • Ear, Nose & Throat • Orthopaedics Arthroscope • Gynaecology • Urology • Keyhole surgery Proctoscope
Slide 20: LMI of Human Colon
LMI of Human Colon Conventional Endoscope LMI of Normal Human Colon
Slide 21: Endo-Microscope Market Info
ENDO-MICROSCOPE MARKET INFO USA Australia New cases of colorectal 143,080 pa* 10,020 pa** cancers pa (mainly colon carcinoma) Colorectal cancer deaths pa* 57,400 pa* 4,600 pa** Direct cost of colorectal cancer US $3.97 billion* ~AUD $160 million** Annual Sales of Gastro- 8,100*** 900*** Endoscopes (
Slide 22: Flexible Endoscopes - Path to Market
Flexible Endoscopes - Path to Market • Optiscan retrofits “insert” into conventional endoscope • Method utilises standard endoscope repair techniques • Optiscan is seeking a partnership with an endoscope manufacturer • Most efficient for endoscope manufacturer to perform integration • Better to team
Slide 23: Rigid Endoscopes - Path to Market
Rigid Endoscopes - Path to Market • Most recent consideration for product development • Optiscan can manufacture • Can develop scanners for fitting to Stratum platform • Does not require integration with existing scope • Partnering options are presently not defined • Partnering for marketing and dis
Slide 24: Medical Advisory Board
Medical Advisory Board USA AUSTRALIA • Allan C Halpern, MD • Michael Freeman, MD Service Chief, Dermatology Service, Dermatologist, Memorial Sloan-Kettering Cancer Center, Gold Coast Hospital, QLD. New York, NY • Prof. Paul O’Brien • Janet Fairley, MD Department Head, Surgery, Professor, Department
Slide 25: Competition
Competition Optiscan Competing Comments Product products Stratum Vivascope by Lucid Not miniaturised; Complementary in market development. Flexible endomicroscope None Others are researching fibre confocal probes; we believe that patent infringement = barrier to entry. Rigid endomicroscope None As a
Slide 26: Consumables & Disposables
Consumables & Disposables • Contrast Agents • Fluorescent Agents which increase contrast • So far, using common clinical agents • Would be packaged for single procedure • Under consideration with dye manufacturers • Not yet a product • Potential for links with therapies • Sheaths/tips • Some procedu
Slide 27: Board and Management
Board and Management • Board Ray Martin Chairman Bruce Andrew Company Secretary Peter Delaney Martin Harris Alan Finkel Keith Daniel Managing Director Director Director Director • Executive management Peter Delaney Managing Director Peter Delaney Russell Thompson Bruce Andrew John Allen Brian Murrih
Slide 28: Financial Outlook
Financial Outlook • June 2001 balance - AUD$7m • Present cash - AUD$6.4m with receipt of $1M final START grant payment • Projected losses ~AUD$5.3M • Royalty income from licences expected to be at least AUD $500K (historically $800K) • AUD $2.5M expected from option exercise • Income from Stratum sa
Slide 29: Summary
Summary • Stratum is underway • Relationships established with multiple US reference sites • First sales • Distribution in five countries to support early adopter market • Positive signs that skin microscopy figures strongly in future of dermatology • Rich product pipeline • Flexible endscopes are n
Slide 30: www.Optiscan.com
www.Optiscan.com Unlocking the world of Live Micro Imaging (LMI) technology
Optiscan Imaging — Shareholder Meeting (November 2001) on 6ix